Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

[1]  J. Hardwicke,et al.  Ten-year audit of melanoma in a central England population. , 2011, Acta dermato-venereologica.

[2]  Q. Mi,et al.  BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. , 2011, The Journal of investigative dermatology.

[3]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Scolyer,et al.  BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.

[5]  K. Flaherty,et al.  Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma , 2011, Clinical Cancer Research.

[6]  C. Cui,et al.  Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases , 2011, BMC Cancer.

[7]  Li-E. Wang,et al.  Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma , 2010, Clinical Cancer Research.

[8]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[9]  M. Brown,et al.  Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. , 2010 .

[10]  Genoa Brisbane.  Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations , 2010 .

[11]  N. Hayward,et al.  The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. , 2010, The Journal of investigative dermatology.

[12]  T. Golub,et al.  Modeling genomic diversity and tumor dependency in malignant melanoma. , 2008, Cancer research.

[13]  T. Saida,et al.  Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update , 2008, International Journal of Clinical Oncology.

[14]  L. Fecher,et al.  Toward a molecular classification of melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[16]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .

[17]  G. Peck,et al.  Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians. , 2007, Journal of drugs in dermatology : JDD.

[18]  J. Lundeberg,et al.  NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.

[19]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Berwick,et al.  Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? , 2006, The Journal of investigative dermatology.

[21]  Stephen B Gruber,et al.  BRAF and NRAS mutations in melanoma and melanocytic nevi , 2006, Melanoma research.

[22]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[23]  A. Benner,et al.  Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases , 2005, Melanoma research.

[24]  K. Hemminki,et al.  BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. , 2005, The Journal of investigative dermatology.

[25]  D. Polsky,et al.  Clinical significance of BRAF mutations in metastatic melanoma , 2004, Journal of Translational Medicine.

[26]  C. Garbe,et al.  Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[28]  D. Morton,et al.  Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas , 2004, Clinical Cancer Research.

[29]  K. Czene,et al.  BRAF mutations in metastatic melanoma: a possible association with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[31]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[32]  L. Kanter,et al.  Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. J. van den Oord,et al.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. , 2001, The Journal of investigative dermatology.

[34]  U. Ringborg,et al.  N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. , 1998, The Journal of investigative dermatology.

[35]  N. Hayward,et al.  Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. , 1996, The American journal of pathology.

[36]  J. Hoeffler,et al.  Ras mutations in human melanoma: a marker of malignant progression. , 1994, The Journal of investigative dermatology.

[37]  C. Cordon-Cardo,et al.  Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. , 1989, Oncogene.

[38]  L. J. Veer,et al.  N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.

[39]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.